1,3,4,7-Tetrahydro-2H-azepin-2-on | 24517-66-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吖庚因类
• 英文名称: 1,3,4,7-Tetrahydro-2H-azepin-2-on
• 英文别名: 6-Amino-4-hexensaeurelactam；1,3,4,7-tetrahydro-azepin-2-one；3,4-Dihydro-1H-azepin-2(7H)-one；1,2,5,6-tetrahydroazepin-7-one
• CAS: 24517-66-6
• 化学式: C₆H₉NO
• mdl: MFCD19218304
• 分子量: 111.144
• InChiKey: DGPWWGHZMIOYFV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1,3,4,7-Tetrahydro-2H-azepin-2-on 以 乙二醇二甲醚 为溶剂， 反应 7.5h， 生成 9a-Dimethylamino-2,3-diphenyl-1-oxo-5,8,9,9a-tetrahydro-1H-pyrrolo<1,2-a>azepin
  参考文献：
  名称：

  Zur Reaktion von Cyclopropenonen mit Azomethinen; VII. Diphenylcyclopropenon und cyclische Amidine: Synthese von bi- und tricyclischen Pyrrolinon-Derivaten

  摘要：

  环丙烯酮与偶氮甲胺的反应；VII，二苯基环丙烯酮与环脒：双环和三环吡咯烷酮衍生物的合成 二苯基环丙烯酮（1）与环脒 2 或 10-13 反应生成不同结构类型的双环和三环吡咯烷酮衍生物（3 或 14-17），这些衍生物可以通过简单的顺序转化为吡咯烷酮簇杂的杂双环和三环化合物（7、18-21）。

  DOI：

  10.1055/s-1985-34144

文献信息

• Interleukin converting enzyme inhibitors
  申请人：The Procter & Gamble Company

  公开号：US20040009966A1

  公开（公告）日：2004-01-15

  The present invention relates to novel compounds, compositions comprising said compounds, and uses thereof, said compounds having the formula: 1 wherein each X is independently selected from: i) —C(W) 2 —; ii) —C(O)—; iii) —NR 2 —; iv) —S—; v) —S(O)—; vi) —S(O) 2 —; vii) two units, one from each adjacent X unit, can be taken together to form a substituted or unsubstituted double bond having the formula —CW═CW—; wherein each W is hydrogen of a unit having the formula —(L 2 ) j —R 2 , the index j is 0 or 1; R is a carbocyclic or heterocyclic aryl ring; R 1 is a cysteine trap; each R 2 is independently a suitable substituent; and L, L 1 , and L 2 are linking units.

  本发明涉及新颖化合物、包含所述化合物的组合物以及它们的用途，所述化合物具有以下结构式：1其中每个X独立地选自：i) —C(W)2—；ii) —C(O)—；iii) —NR2—；iv) —S—；v) —S(O)—；vi) —S(O)2—；vii) 两个单元，来自相邻的每个X单元，可以结合在一起形成具有结构式—CW═CW—的取代或未取代的双键；其中每个W是具有结构式—(L2)j—R2的单位的氢，指数j为0或1；R是一个碳环或杂环芳基；R1是一个半胱氨酸陷阱；每个R2独立地是一个合适的取代基；L、L1和L2是连接单元。
• PEPTIDE DEFORMYLASE INHIBITORS
  申请人：Qin Donghui

  公开号：US20090306066A1

  公开（公告）日：2009-12-10

  The present invention is directed to certain 2-(alkyl)-3-[2-(5-fluoro-4-pyrimidinyl)hydrazino]-3-oxopropyl}hydroxyformamide derivatives, compositions containing them, the use of such compounds in the inhibition of bacterial peptide deformylase (PDF) activity, and in the treatment of bacterial infections. Specifically, the invention is directed to compounds of formula (I): wherein R1, R2 and R3 are defined herein and to pharmaceutically acceptable salts thereof. The compounds of this invention are bacterial peptide deformylase inhibitors and can be useful in the treatment of bacterial infections.

  本发明涉及某些2-(烷基)-3-[2-(5-氟-4-嘧啶基)肼基]-3-氧代丙基}羟基甲酰胺衍生物，包含它们的组合物，这些化合物在抑制细菌肽变形酶（PDF）活性和治疗细菌感染方面的使用。具体而言，本发明涉及式（I）的化合物：其中R1，R2和R3在此定义，并且其药学上可接受的盐。本发明的化合物是细菌肽变形酶抑制剂，可用于治疗细菌感染。
• EICHER, TH.;ROHDE, R., SYNTHESIS, BRD, 1985, N 6-7, 619-625
  作者：EICHER, TH.、ROHDE, R.

  DOI：——

  日期：——
• PROCESS FOR PURIFYING CAPROLACTAM
  申请人：DSM IP Assets B.V.

  公开号：EP1648865B1

  公开（公告）日：2010-04-21
• Process for purifying caprolactam
  申请人：Lemmens J.A.W. Joannes Albertus Wilhelmus

  公开号：US20070060750A1

  公开（公告）日：2007-03-15

  The invention relates to a process for purifying caprolactam, said process comprising (a) subjecting the caprolactam to a hydrogenation by treating the caprolactam with hydrogen in the presence of a heterogeneous nickel containing hydrogenation catalyst, (b) distilling at least a portion of the hydrogenated caprolactam in a distillation column containing nickel in an amount sufficiently low such that ΔPAN Ni ≦3, wherein ΔPAN Ni =ΔPAN=ΔPAN Ni=0 , ΔPAN=increase of the PAN number of caprolactam during distilling, ΔPAN Ni=0 increase of the PAN number of caprolactam during distilling under the same conditions in a distillation column free of nickel. Nickel is removed from the caprolactam solution prior to the distillation step.